睿知中国医院研究地图
候选清单

正在招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由中国医学科学院血液病医院(血液学研究所)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06996132,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 65 岁;性别:不限

    登记记录的入选字段

  2. Biopsy-proven residual disease following initial therapy.

    入选标准第 10 条

  3. ≥2 prior lines of therapy (including both anti-CD20 monoclonal antibody and anthracycline-based chemotherapy) with documented progression following last treatment; OR

    入选标准第 3 条

    Persistent metabolic activity (Deauville 5) on PET-CT after 2 cycles of first-line immunochemotherapy; OR

    入选标准第 9 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

    入选标准第 12 条

  5. Absolute neutrophil count (ANC) ≥1×10⁹/L,

    入选标准第 14 条

    Platelet count (PLT) ≥75×10⁹/L.

    入选标准第 15 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN);

    入选标准第 17 条

    Total bilirubin (TBIL) ≤1.5×ULN (unless due to Gilbert's syndrome or non-hepatic causes);

    入选标准第 18 条

    Serum creatinine (Cr) ≤2×ULN OR creatinine clearance ≥40 mL/min.

    入选标准第 19 条

  6. Active HBV or HCV infection, defined as HBV-DNA or HCV-RNA levels above the upper limit of detection.

    排除标准第 3 条

    HIV infection;

    排除标准第 7 条

  7. Pregnancy or lactation;

    排除标准第 6 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06996132,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients with relapsed/refractory aggressive B-cell lymphoma, including the following subtypes: diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), or transformed large B-cell lymphoma.
  2. Relapsed or refractory disease, meeting criteria for one of the following cohorts:
  3. ≥2 prior lines of therapy (including both anti-CD20 monoclonal antibody and anthracycline-based chemotherapy) with documented progression following last treatment; OR
  4. Failure of first-line immunochemotherapy (containing anti-CD20 antibody and anthracycline) defined by any of:
  5. Relapse/progression within 12 months of treatment completion; OR
  6. Progressive disease during first-line therapy; OR
  7. Stable disease as best response after 4 cycles; OR
  8. Partial response as best response after 6 cycles.
  9. Persistent metabolic activity (Deauville 5) on PET-CT after 2 cycles of first-line immunochemotherapy; OR
  10. Biopsy-proven residual disease following initial therapy.
  11. Age ≥18 years and ≤65 years.
  12. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  13. Hematologic parameters at screening must meet the following (unless due to bone marrow involvement):
  14. Absolute neutrophil count (ANC) ≥1×10⁹/L,
  15. Platelet count (PLT) ≥75×10⁹/L.
  16. Biochemical parameters at screening must meet the following:
  17. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN);
  18. Total bilirubin (TBIL) ≤1.5×ULN (unless due to Gilbert's syndrome or non-hepatic causes);
  19. Serum creatinine (Cr) ≤2×ULN OR creatinine clearance ≥40 mL/min.
  20. Left ventricular ejection fraction (LVEF) within institutional normal range by echocardiography.
  21. Baseline oxygen saturation >92% on room air.
  22. Life expectancy ≥3 months as assessed by the investigator.

排除标准:Exclusion Criteria:

  1. Confirmed primary central nervous system lymphoma;
  2. Prior autologous or allogeneic hematopoietic stem cell transplantation;
  3. Active HBV or HCV infection, defined as HBV-DNA or HCV-RNA levels above the upper limit of detection.
  4. Uncontrolled comorbidities include infectious diseases, cardiovascular/cerebrovascular disorders, coagulopathies, and connective tissue diseases.
  5. History of epilepsy or other central nervous system disorders;
  6. Pregnancy or lactation;
  7. HIV infection;
  8. History of other malignancies unless:
  9. Disease-free for ≥5 years, or
  10. Previously cured of the following:
  11. Non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma, or related localized cutaneous malignancies)
  12. Carcinoma in situ of cervix
  13. Other conditions deemed ineligible by investigators.

引自 ClinicalTrials.gov, NCT06996132, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06996132,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06996132